Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Stock Report

Mkt Cap: US$174.0m

Citius Pharmaceuticals Past Performance

How has Citius Pharmaceuticals performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CTXR is currently unprofitable.

Growing Profit Margin: CTXR is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CTXR is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.

Accelerating Growth: Unable to compare CTXR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTXR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.4%).

Return on Equity

High ROE: CTXR has a negative Return on Equity (-32.53%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies